Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its
presentation at the 8th Annual Needham Life Sciences
Conference on Thursday, June 11, 2009. The presentation, which is
scheduled for 2:30 p.m. Eastern Time, will provide an overview of the
Company, including its three Phase 3 clinical programs. The session may
be accessed through the Company’s web site, www.regeneron.com,
on the Investor Relations page under the Presentations heading. An
archived version of the presentation will be available after the live
webcast through July 11, 2009. Additional information about Regeneron
and recent news releases are available on the Regeneron web site.
Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment of
serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first commercialized
product, Regeneron has therapeutic candidates in clinical trials for the
potential treatment of cancer, eye diseases, inflammatory diseases, and
pain, and has preclinical programs in other diseases and disorders.
Regeneron Pharmaceuticals, Inc.
Peter Dworkin, 914-345-7640
Investor
Relations
peter.dworkin@regeneron.com
or
Laura
Lindsay, 914-345-7800
Media Relations
laura.lindsay@regeneron.com
or
Olga
Fleming, 212-845-5636
Media Relations
ofleming@biosector2.com
